Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic information is available nowadays concerning desvenlafaxine, its active metabolite first marketed in 2012. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Calleja, Sofía, Zubiaur, Pablo, Ochoa, Dolores, Villapalos-García, Gonzalo, Mejia-Abril, Gina, Soria-Chacartegui, Paula, Navares-Gómez, Marcos, de Miguel, Alejandro, Román, Manuel, Martín-Vílchez, Samuel, Abad-Santos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934922/
https://www.ncbi.nlm.nih.gov/pubmed/36817149
http://dx.doi.org/10.3389/fphar.2023.1110460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934922/
https://www.ncbi.nlm.nih.gov/pubmed/36817149
http://dx.doi.org/10.3389/fphar.2023.1110460

Ejemplares similares